CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 20,000 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Key inclusion· 2
  • Suspicion or confirmed diagnosis of primary breast cancer
  • Signed informed consent
Key exclusion· 1
  • Lack of signed informed consent

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02306096
NCT02306096N/ARecruitingHigh MomentumUpdated 28mo ago
Long Recruiting

SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative

Lund University·observational·Posted Dec 3, 2014·Updated Feb 9, 2024

In Brief

An observational study for Breast Neoplasms. Currently recruiting, targeting 20,000 participants across 9 sites.

Signals

Enrolling ahead of pace

Detailed Summary

This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSweden

Timeline

N/ARecruiting
20102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032
First PostedDec 3, 2014
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2031
TodayJul 2, 2026
Enrollment to primary: 21 yearsPosted 11.6 years agoPrimary completion in 5.1 years